LONDON–(BUSINESS WIRE)–#Biotechnology–The high prevalence of genitourinary diseases is one of the critical reasons that will drive genitourinary drugs market growth. Bacterial infections or STDs can cause genitourinary disorders. It also includes various carcinomas such as ovarian cancer, cervical cancer, bladder cancer, and prostate cancer. Age-related ailments such as Alzheimer’s and disorders like diabetes, obesity, and multiple sclerosis are also significantly responsible for genitourinary conditions. Additionally, there is also a growing incidence of incontinence and interstitial cystitis. This will increase the consumption of genitourinary drugs, in turn, driving market growth. Furthermore, this industry research report also presents a competitive analysis of the market by type (genital diseases and urinary diseases) and geography (Asia, Europe, North America, and ROW).
Competitive vendor landscape
The global genitourinary drugs market is highly competitive with major vendors such as Astellas Pharma Inc., AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., and Novartis AG., competing on the basis of price, quality, and product/service offerings.
“North America will account for the highest genitourinary drugs market share throughout the forecast period. The increasing prevalence of STDs, the rise in geriatric population, and new research activities towards the development of treatment methods are significant factors contributing to the growth of the genitourinary drugs market in this region,” says a senior analyst at Technavio
Top five genitourinary drugs vendors
Astellas Pharma Inc.
Astellas Pharma Inc. manufactures and sells pharmaceutical products. The company’s key offerings include: ELIGARD, Myrbetriq, VESIcare, and XTANDI.
AstraZeneca runs its operations through the biopharmaceuticals segment. This segment focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of unmet medical needs in three therapy areas, namely oncology, respiratory, and cardiovascular and metabolic diseases. The company’s key offerings include: IMFINZI and LYNPARZA.
Eli Lilly and Company
Eli Lilly and Company runs its operations through two segments: human pharmaceutical products and animal health products. The company’s key offering includes CIALIS. CIALIS (tadalafil) is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It is available as tablets for oral administration. It is indicated for the treatment of erectile dysfunction.
Johnson & Johnson Services, Inc.
Johnson & Johnson Services, Inc. runs its operations through three segments: consumer, pharmaceutical, and medical devices. The company’s key offerings for this market include ERLEADA and ZYTIGA.
Novartis AG runs its operations through three segments: innovative medicines, sandoz, and alcon. The company’s key offering for this market include AFINITOR and VOTRIENT.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Pruritus Drugs Market 2019-2023 – The market research study identifies Allergan Plc, Astellas Pharma Inc., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi, as the leading players in the global pruritus drugs market.
- Global Uveitis Drugs Market 2019-2023 – The market research study identifies AbbVie Inc., Allergan Plc, Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc., as the leading players in the global uveitis drugs market.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at [email protected].